Sign In
Buy ZNTL
$4.74
-0.180 (-3.66%)
At Close: Jul 31, 2026
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
04:15pm, Thursday, 28'th Aug 2025
SAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1
Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary
04:05pm, Tuesday, 26'th Aug 2025
Seasoned life sciences legal executive brings extensive public company experience, including broad strategic and financial transaction expertise Seasoned life sciences legal executive brings extensive
Zentalis (ZNTL) Q2 Loss Narrows 70%
08:28pm, Wednesday, 06'th Aug 2025
Zentalis Pharmaceuticals (ZNTL -2.13%), a clinical-stage biopharmaceutical company focused on developing cancer therapies, released its second quarter earnings on August 6, 2025. The headline news was
Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress
04:05pm, Wednesday, 06'th Aug 2025
DENALI Phase 2 trial evaluating azenosertib in patients with Cyclin E1-positive PROC remains on track with topline data anticipated by year end 2026, with the potential to support an accelerated appro
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05:00pm, Tuesday, 01'st Jul 2025
SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05:00pm, Monday, 02'nd Jun 2025
SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1
Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress
04:05pm, Wednesday, 14'th May 2025
First patient dosed in DENALI Part 2a clinical trial of azenosertib in patients with Cyclin E1+ PROC Topline data from DENALI Part 2 anticipated by year end 2026 with the potential to support an accel
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05:00pm, Thursday, 01'st May 2025
SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 i
Phase 2 registration-intent trial enrolling Part 2a dose confirmation arms Topline data from DENALI Part 2 anticipated by year end 2026 with the potential to support an accelerated approval, subject t
Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting
04:05pm, Wednesday, 23'rd Apr 2025
SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05:30pm, Tuesday, 01'st Apr 2025
SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1
Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates
04:05pm, Wednesday, 26'th Mar 2025
Positive azenosertib clinical data demonstrated clinically meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC)
Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025
04:40pm, Tuesday, 25'th Mar 2025
One poster demonstrating cell-free DNA molecular response as a potential surrogate endpoint to measure clinical efficacy of azenosertib in patients with high-grade serous ovarian cancer (HGSOC)
Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer
11:25am, Saturday, 15'th Mar 2025
Azenosertib median duration of response (mDOR) updated to 6.3 months in the ongoing DENALI Part 1b clinical trial in patients with platinum-resistant ovarian cancer (PROC) and continues to demonstrate
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05:00pm, Monday, 03'rd Mar 2025
SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1
